Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 201.29

+0.2%

Nov 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Webhead who wrote (20559)	5/12/1998 7:36:00 AM
From: Henry Niman	Read Replies (1) of 32384

Here's a couple additional protocols for ONTAK: DAB 389 IL-2 (93-04-11) This is a Randomized, Double-blinded, Placebo Controlled Study to Evaluate the Efficacy of Two-Dose Levels of DAB389IL-2 in Cutaneous T-cell Lymphoma (CTCL). Patients with Stage Ia-III disease who have had <3 previous therapies and have recurrent or persistent disease will receive DAB389IL-2 as a 15 minute IV infusion for 5 consecutive days, every 21 days for a maximum of 6 months. DAB 389 IL-2 (93-04-14) A multi-center phase III, open-label DAB389 IL-2 study for patients with Stage Ia-IVa CTCL who have recurrent or persistent disease. Patients following protocol 93-04-10, protocol 93-04-11 or protocol 92-04-01 are eligible. Patients will receive DAB389 IL-2 as a 15 minute IV infusion for 5 consecutive days, every 21 days for a maximum of 6 months.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next